Maenclad (Mavenclad / Cladribine): Short-Course Oral MS Therapy

By Dr. Emily Hanover

Maenclad (Mavenclad/Cladribine): Short-Course Oral MS Therapy by Dr. Emily Hanover is a comprehensive guide to understanding one of the most innovative treatment options for multiple sclerosis (MS). This book delves into the science behind Cladribine, explaining its mechanism of action, clinical efficacy, and role in the evolving landscape of MS therapy.

Unlike traditional disease-modifying therapies that require continuous administration, Maenclad offers a short-course oral regimen, reducing the treatment burden while maintaining long-term benefits. Dr. Hanover explores how this unique dosing structure impacts patient adherence, safety, and effectiveness.

Readers will gain insight into the history of multiple sclerosis research, the development of Cladribine as an MS therapy, and its comparative effectiveness against other treatments. The book also addresses key considerations such as pre-treatment screening, potential side effects, and long-term safety data.

Drawing on clinical trial findings and real-world patient experiences, Maenclad provides an in-depth yet accessible resource for individuals living with MS, healthcare professionals, and anyone seeking a deeper understanding of this groundbreaking therapy. Whether you are considering Maenclad as a treatment option or simply want to expand your knowledge of MS management, this book offers valuable, research-backed insights into the future of MS treatment.

• Format: Paperback
• Language: English
• ISBN: B0F19CRT8J
• ISBN13: 9798313827841
• Release Date: March 2025
• Publisher: Independently Published
• Length: 208 Pages
• Weight: 0.63 lbs.
• Dimensions: 0.4" x 6.0" x 9.0"